한빛사논문
- 조회400
Xingshu Li1†, Jae Sang Oh2,3†, Yoonji Lee4†, Eun Chae Lee2, Mengyao Yang5, Nahyun Kwon5, Tae Won Ha6, Dong‑Yong Hong2, Yena Song6, Hyun Kyu Kim6, Byung Hoo Song6, Sun Choi7*, Man Ryul Lee6* and Juyoung Yoon5*
1Fujian Provincial Key Laboratory for Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou, China.
2Department of Neurosurgery, College of Medicine, Cheonan Hospital, Soonchunhyang University, Cheonan‑si, Chungcheongnam‑do, Republic of Korea.
3Department of Neurosurgery, Uijeonbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
4College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
5Department of Chemistry and Nanoscience, Ewha Womans University, Seoul, Republic of Korea.
6Soonchunhyang Institute of Medi‑bio Science (SIMS), Soonchunhyang University, Cheonan‑si, Chungcheongnam‑do, Republic of Korea.
7Global AI Drug Discovery Center, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.
†Xingshu Li, Jae Sang Oh and Yoonji Lee contributed equally to this work.
*Correspondence: Sun Choi, Man Ryul Lee, Juyoung Yoon
Abstract
Background: Malignant glioma is among the most lethal and frequently occurring brain tumors, and the average survival period is 15 months. Existing chemotherapy has low tolerance and low blood-brain barrier (BBB) permeability; therefore, the required drug dose cannot be accurately delivered to the tumor site, resulting in an insufficient drug effect.
Methods: Herein, we demonstrate a precision photodynamic tumor therapy using a photosensitizer (ZnPcS) capable of binding to albumin in situ, which can increase the permeability of the BBB and accurately target glioma. Albumin-binding ZnPcS was designed to pass through the BBB and bind to secreted protein acidic and rich in cysteine (SPARC), which is abundant in the glioma plasma membrane.
Results: When the upper part of a mouse brain was irradiated using a laser (0.2 W cm- 2) after transplantation of glioma and injection of ZnPcS, tumor growth was inhibited by approximately 83.6%, and the 50% survival rate of the treatment group increased by 14 days compared to the control group. In glioma with knockout SPARC, the amount of ZnPcS entering the glioma was reduced by 63.1%, indicating that it can target glioma through the SPARC pathway.
Conclusion: This study showed that the use of albumin-binding photosensitizers is promising for the treatment of malignant gliomas.
논문정보
- Research article
- 2023년 03월 (BRIC 등록일 2023-04-17)
- 국내(교신)+국외 연구진
- 의약학 > 약학
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
관련분야 논문보기
